Arcutis Biotherapeutics Inc Stock
Arcutis Biotherapeutics Inc Stock price
Key metrics
| Market capitalization | $1.21b |
| Enterprise Value | $1.06b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 7.99 |
| P/S ratio (TTM) P/S ratio | 9.17 |
| P/B ratio (TTM) P/B ratio | 6.47 |
| Revenue growth (TTM) Revenue growth | 1,032.90% |
| Revenue (TTM) Revenue | $132.06m |
Is Arcutis Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
Arcutis Biotherapeutics Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:
Analyst Opinions
7 Analysts have issued a Arcutis Biotherapeutics Inc forecast:
Financial data from Arcutis Biotherapeutics Inc
| Jun '24 |
+/-
%
|
||
| Revenue | 132 132 |
3,479%
3,479%
|
|
| Gross Profit | 122 122 |
6,007%
6,007%
|
|
| EBITDA | -178 -178 |
41%
41%
|
EBIT (Operating Income) EBIT | -180 -180 |
40%
40%
|
| Net Profit | -199 -199 |
36%
36%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Arcutis Biotherapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcutis Biotherapeutics Inc Stock News
Company Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.
| Head office | United States |
| CEO | Todd Watanabe |
| Employees | 296 |
| Founded | 2016 |
| Website | www.arcutis.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
